News
Neupulse celebrates recognition at the Medilink Midlands Awards
It was an extraordinary evening for Neupulse on the 9th May as our team had the pleasure of attending the distinguished Medilink Midlands awards. We were honoured to be nominated in four highly competitive categories showcasing the incredible talent and innovation thriving in the region. The awards we contested were: Partnership between Academia and Business Innovation Achievement One to Watch Each category featured between three to six nominees demonstrating the high calibre of competition. Neupulse stood out receiving high commendations in two categories: Partnership between Academia and Business and Innovation. This recognition is particularly significant considering over one hundred companies applied for all of the award categories making it a remarkable achievement for our team. These commendations serve not only as a testament to our team's hard work and dedication but also highlight the impactful contributions Neupulse is making in the healthcare and technological sectors by advancing treatment and support options for individuals with Tourette Syndrome. Let's celebrate these achievements and continue to strive for excellence. For further details please visit: Medilink Midlands
Learn more
Neupulse is nominated in 4 categories at the Medilink Midlands awards
We are delighted to be nominated for 4 awards at the Medilink awards to be held on 9 May. The awards are designed to recognise and celebrate the best of innovation, collaboration and connectivity in the life sciences and medtech sector within the Midlands. The categories we have been nominated for include: Innovation One to watch Partnership between Academia and Business Outstanding Achievement
Learn more
Neupulse secures funding to advance world’s first wearable device to tackle Tourettes Syndrome
Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialisation. Neupulse’s recently finalised working prototype stimulates the median nerve in the wrist, reducing the frequency of tics in individuals with TS, a condition that is thought to affect as much as 2 per cent of the world’s child population and 1 per cent of the overall population. Clinical trials in 2023 showed the Neupulse device can reduce tics by over 25 percentile. Neupulse has secured a £2.5 million seed stage investment led by Scottish impact investor Eos Advisory, alongside a consortium including US-based investors, as Neupulse moves towards regulatory approval phase in the UK, Europe, and the USA. Tourettes Syndrome is a neurological condition characterised by involuntary, repetitive movements and vocalisations known as tics. The causes of TS and other tic disorders remain unclear, but genetic and environmental factors are known to play a role. TS can cause significant pain and discomfort for those affected, through the hundreds of daily involuntary and often violent motions, in addition to impacting social integration in schooling, work, and wider society. Paul Cable, CEO of Neupulse, said: “Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals. Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the TS community globally in the years ahead.” Ana Stewart, Partner, Eos Advisory, said: “Eos was set up to back science-based companies and founders developing technologies that can positively impact the lives of people across the globe. Whilst we are focussed on Scottish startups, when one of our investors brought the amazing work of Neupulse to our attention we realised that there was a huge opportunity to add value, well beyond the investment, to help bring this device to market and improve the lives of people affected by TS and related conditions. What’s even more exciting, is how the nascent technology could be beneficial for many other neural conditions in the future.”
Learn more
Neupulse wearable device for Tourette Syndrome wins Knowledge Exchange and Impact award
The University of Nottingham's Knowledge Exchange and Impact Awards recently honoured Professor Stephen Jackson's team at the University of Nottingham and Neurotherapeutics Ltd with the Science Faculty's award for Professor Stephen Jackson's groundbreaking research leading to the innovative Neupulse technology and for Neurotherapeutics Ltd’s work resulting in the Neupulse technology being developed into a wearable device to alleviate symptoms for individuals with Tourette Syndrome. The award celebrates the project's societal impact, highlighting the device's global potential to positively influence the lives of those living with Tourette Syndrome and their families. It recognised the collaborative efforts from researchers at the University of Nottingham and the team at Neurotherapeutics Ltd in striving to make a meaningful difference.
Learn more
Research by the University of Nottingham wins prestigious STEM Research Project of the Year at THE Awards
In significant recognition of innovation and excellence in higher education, the University of Nottingham's groundbreaking research resulting in the Neupulse technology being developed into a wearable device to alleviate symptoms for individuals with Tourette Syndrome by Neurotherapeutics Ltd has been awarded the prestigious Science, Technology, Engineering and Maths Research Project of the Year at the Times Higher Education Awards 2023. The awards, often dubbed the 'Oscars of higher education' are a hallmark of excellence across the UK and Ireland's higher education sector. Professor Stephen Jackson from the University of Nottingham's School of Psychology and Chief Scientific Officer at Neurotherapeutics Ltd has been at the forefront of the groundbreaking research leading to the innovative technology which is now evolving into a wearable device under the stewardship of Neurotherapeutics Ltd. Professor Jackson said: "We're honoured to receive this award for our research. We have always been driven by a desire to make a real difference in the lives of those with Tourette Syndrome. We're excited about the potential of the Neupulse wrist device being developed by Neurotherapeutics Ltd to bring significant improvements to their daily lives.” The recognition at THE Awards is a testament to the project's groundbreaking potential.
Learn more
Neupulse inspired by TICfest, organised by Tourettes Action
Neupulse is excited to share the success of TICfest, a heartwarming event organised by Tourettes Action that brought together individuals with Tourette Syndrome and their families. It was a day of connection, learning and community. Dr Barbara Morera and CEO Paul Cable delivered three engaging talks, highlighting the journey and impact of the Neupulse technology on the management of tics. Their presentations were a mix of scientific insight and real-life impact, inspiring hope and understanding. The event emphasised the strength and resilience of the Tourette Syndrome community. We thank Tourettes Action for making TICfest a memorable and enriching experience.
Learn more
Neupulse at TicFest
Exciting times ahead! We're thrilled to announce that Neupulse will be participating in the upcoming TicFest on the 3rd of December, an inspiring event organised by Tourettes Action, dedicated to supporting individuals and families living with Tourette Syndrome (TS). We are delighted to share that the event is now fully booked reflecting the incredible enthusiasm and support within the TS community. Our CEO, Paul Cable and Chief Research Officer, Dr Barbara Morera will be attending this special gathering bringing with them a prototype of our groundbreaking medical device designed for the management of tics. Please note that the device will be used only for demonstration purposes and will not be functional at the event. During the event we will present a short session detailing the Neupulse story from our early research days to the exciting road toward bringing our device to people who need it. This talk will cover the development stages of our medical device, emphasizing the unique challenges and triumphs we've encountered along the way. Most importantly we're excited to share the promising results from our clinical trial completed earlier this year, which marks a significant advancement in Tourette's treatments. Our presence at TicFest aligns perfectly with our mission to engage with the TS community, gain valuable insights and contribute to a supportive environment for individuals living with this condition. We believe that sharing our journey and the clinical trial outcomes will not only showcase our commitment to innovative healthcare solutions but also offer hope and encouragement to those impacted by TS. For those who have secured a ticket we look forward to seeing you there!
Learn more
Leading Tourette Syndrome Expert Professor Stephen Jackson invited to talk about Neupulse’s Research and Tourette Syndrome at different November events
This month, Neupulse has the honour of announcing that our Chief Scientific Officer, Professor Stephen Jackson, recognised as one of the foremost experts in the field of Tourette Syndrome, has been invited to discuss our transformative research at several esteemed events as well as shedding light on the latest advancements in understanding Tourette Syndrome. Event Highlights: 10th November: Professor Jackson was invited to talk at the Midlands Neurology Society about the latest findings in the field of Tourette Syndrome including Neupulse research. 15th November: Professor Jackson was invited to talk at the Norsk Tourette Forening (Norwegian Tourette’s group) about Neupulse research. 22nd November: The Federation of European Societies for Neuropsychology welcomes Professor Jackson to contribute his expertise in a webinar focusing on the neuropsychology of involuntary movements a cornerstone of Tourette syndrome research. These invitations underscore the international recognition of Professor Jackson's significant contributions to the field and Neupulse's role in pioneering research that promises to enhance the current treatment of Tourette Syndrome.
Learn more
Neupulse’s innovative device shortlisted for THE Awards 2023 in STEM research category
We're excited to announce that Neupulse’s groundbreaking medical device has been shortlisted for the Science, Technology, Engineering and Maths (STEM) Research Project of the Year at the 2023 Times Higher Education (THE) Awards. This prestigious honour recognises our innovative contributions to revolutionise the way individuals with Tourette syndrome experience relief from their symptoms. Being shortlisted is a testament to the hard work of our team. We extend our thanks to everyone who has been part of this journey. Winners will be announced on 7th of December 2023. Thank you for your continuous support!
Learn more